menu
    • menu
    [{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Habekacin","moa":"Bacterial 30S ribosomal RNA (Bact 30S rRNA)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"OP0595","moa":"Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Luliconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amenamevir","moa":"Helicase primate complex","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAK-671","moa":"sEH","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"The University Of Tokyo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Daiichi Sankyo \/ The University Of Tokyo","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ The University Of Tokyo"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"fH1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"National Institutes of Biomedical Innovation, Health and nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DSP-0546LP","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sumitomo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma \/ National Institutes of Biomedical Innovation, Health and nutrition"},{"orgOrder":0,"company":"KM Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"KD-414","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KM Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"KM Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"KM Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Rohto Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Rohto Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rohto Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rohto Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"NoV GI.1\/GII.4 Bivalent VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"NITTO DENKO CORP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NSV0001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"NITTO DENKO CORP","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NITTO DENKO CORP \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NITTO DENKO CORP \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TAK-426","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Secutrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

                            Details : S-892216 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 27, 2024

                            Lead Product(s) : Secutrelvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sumitomo Pharma

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sumitomo Pharma

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : fH1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influen...

                            Details : FH1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 14, 2024

                            Lead Product(s) : fH1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sumitomo Pharma

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sumitomo Pharma

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : fH1,DSP-0546LP

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : National Institutes of Biomedical Innovation, Health and nutrition

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sumitomo and Japan National Institute's universal influenza vaccine enters clinical trials

                            Details : fH1/DSP-0546LP is a vaccine candidate, specifically activates TLR7, being investigated for influenza.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 22, 2024

                            Lead Product(s) : fH1,DSP-0546LP

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Biomedical Innovation, Health and nutrition

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sato Yakuhin Kogyo Co., Ltd

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luliconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis

                            Details : Luliconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Onychomycosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 08, 2021

                            Lead Product(s) : Luliconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Daiichi Sankyo

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS-5670

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Daiichi Sankyo Announces Development Progress of mRNA COVID19 Vaccine in Japan

                            Details : DS-5670, an mRNA vaccine, being evaluated against the novel coronavirus infectious disease (COVID-19). DS-5670 induced a neutralizing activity against previously designated Variant of Concerns, including the Delta variant.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 21, 2021

                            Lead Product(s) : DS-5670

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ensitrelvir Fumaric Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference

                            Details : S-217622 suppresses the duplication of SARS-CoV-2 by selectively inhibiting 3CL protease, an orally administered antiviral drug for COVID-19, caused by the novel coronavirus (SARS-CoV-2).

                            Product Name : Xocova

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 21, 2021

                            Lead Product(s) : Ensitrelvir Fumaric Acid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefiderocol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Joseph Kuti

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cefiderocol PK in Patients on ECMO

                            Details : Cefiderocol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sepsis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 09, 2021

                            Lead Product(s) : Cefiderocol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Joseph Kuti

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Daiichi Sankyo

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VN-0200

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects

                            Details : VN-0200 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 04, 2021

                            Lead Product(s) : VN-0200

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Daiichi Sankyo

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Daiichi Sankyo Initiates Phase 1 Trial for Nafamostat Inhalation Formulation (DS-2319) in Japan

                            Details : DS-2319 contains nafamostat mesilate that has been formulated in an inhalation dosage form. It is being studied for treating COVID-19 since it has been shown to block membrane fusion between the viral envelope that causes COVID-19 and the host plasma cel...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2021

                            Lead Product(s) : Nafamostat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            KM Biologics

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            KM Biologics

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KD-414

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Japan's KM Biologics Begins Clinical Trial of COVID-19 Vaccine Candidate

                            Details : The first volunteer was injected with the inactivated virus vaccine known as KD-414, the company said in a release. The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune r...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : KD-414

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth